Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) finished Friday with an addition of $0.74 to close at $21.83, an upside of 3.51 percent. An average of 383,220 shares of common stock have been traded in the last five days. There was a gain of $0.60 in the past week, and it reached a new high 34 times over the past 12 months. The last 20 days have seen an average of 502,800 shares traded, while the 50-day average volume stands at 826,040.
DRNA stock has increased by 3.80% in the last month. The company shares reached their 1-month lowest point of $19.06 on 10/06/21. With the stock rallying to its 52-week high on 07/20/21, shares of the company touched a low of $18.96 and a high of $40.14 in 52 weeks. It has reached a new high 28 times so far this year and lost -0.91% or -$0.20 in price. In spite of this, the price is down -45.62% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
36 days have passed since Dicerna Pharmaceuticals Inc. (DRNA) last reported insider trading activity. Brown Bob D, who is Chief Scientific Ofr., EVP R&D, most recently acquired $21,250 shares at $21.06 per share on Sep 17. In this transaction, the insider spent $447,516. EVP & Chief Medical Officer, Aradhye Shreeram, disposed of 2,056 shares at a price of $21.47 on Sep 17. The insider now owns more than $44,142 worth of shares. Prior to that, Chief Legal Officer & Sec’y Zeng Ling went on to Sale 1,334 shares at $21.47 each on Sep 17. An amount of $28,641 was transacted.
Dicerna Pharmaceuticals Inc. (DRNA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.43 for the sector. The stock’s beta is 0.95. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.52, the price-to-book (PB) ratio at 15.16, and the price-to-cash flow ratio at 152.01.
The quick ratio of Dicerna Pharmaceuticals Inc. for the three months ended June 29 was 3.00, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Dicerna Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -67.55%, while its operating margin for the same period stands at -69.30%. Its gross profit as reported stood at $277.51 million compared to revenue of $164.31 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Dicerna Pharmaceuticals Inc.’s return on assets was -17.80%. For the broader industry, ROE averaged -68.79 over the past year.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$40.82 million in the quarter, while revenues of -$29.97 million were grew 22.05%. The analyst consensus anticipated Dicerna Pharmaceuticals Inc.’s latest quarter earnings to come in at $0.41 per share, but it turned out to be -$0.53, a -229.30% surprise. For the quarter, EBITDA amounted to -$37.4 million. Shareholders own equity worth $77.73 million.
From a technical analysis perspective, let’s take a brief look at Dicerna Pharmaceuticals Inc. (DRNA) price momentum. RSI 9-day as of the close on 22 October was 67.27%, suggesting the stock is Neutral, with historical volatility in this time frame at 27.24%.
As of today, DRNA’s price is $21.07 +2.83% or $0.60 from its 5-day moving average. DRNA is currently trading +2.49% higher than its 20-day SMA and -27.52% lower than its 100-day SMA. However, the stock’s current price level is +5.05% above the SMA50 and -4.92% below the SMA200.
The stochastic %K and %D were 83.60% and 77.05%, respectively, and the average true range (ATR) was 0.74. With the 14-day stochastic at 97.54% and the average true range at 0.81, the RSI (14) stands at 57.84%. The stock has reached 0.19 on the 9-day MACD Oscillator while the 14-day reading was at 0.64.
Goldman downgraded Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy.